OBJECTIVE: To define the musculoskeletal syndrome associated with use of aromatase inhibitors (AIs), specifically, to describe its incidence, time to onset, risk factors, and clinical presentation. METHODS: Postmenopausal women with hormone-sensitive, nonmetastatic breast cancer starting AI therapy were enrolled in this prospective cohort study. They underwent complete rheumatologic evaluation and contrast-enhanced magnetic resonance imaging (MRI) of the hands and wrists prior to starting AI, at 3 and 6 months. The primary outcome was change in grip strength. RESULTS: Twenty-eight (54%) of 52 women reported new or worsening musculoskeletal symptoms. Two discontinued AIs due to pain. Mean time to symptom onset was 6 weeks (range 2-18 weeks), and 75% of symptomatic patients developed symptoms by 8 weeks. Later-stage cancer and worse quality of life (QOL) pretreatment were significantly associated with symptom development. Sixty-eight percent of symptomatic subjects had involvement of the hands; however, there was no difference in the mean change in grip strength (-2.9 kg versus -1.3 kg; P = 0.6). Among symptomatic subjects, 46% had evidence of focal tenosynovitis of the hands and feet on examination. Although some symptomatic subjects had new MRI abnormalities, Rheumatoid Arthritis Magnetic Resonance Imaging Scoring did not significantly change. CONCLUSION: The incidence of AI-associated musculoskeletal syndrome is more than 50%, with most women developing symptoms by 8 weeks. The key finding in symptomatic women was focal tenosynovitis of the hands and feet, without evidence of autoimmune disease or systemic inflammation. Later-stage cancer and poorer QOL were predictive of symptom development.
OBJECTIVE: To define the musculoskeletal syndrome associated with use of aromatase inhibitors (AIs), specifically, to describe its incidence, time to onset, risk factors, and clinical presentation. METHODS: Postmenopausal women with hormone-sensitive, nonmetastatic breast cancer starting AI therapy were enrolled in this prospective cohort study. They underwent complete rheumatologic evaluation and contrast-enhanced magnetic resonance imaging (MRI) of the hands and wrists prior to starting AI, at 3 and 6 months. The primary outcome was change in grip strength. RESULTS: Twenty-eight (54%) of 52 women reported new or worsening musculoskeletal symptoms. Two discontinued AIs due to pain. Mean time to symptom onset was 6 weeks (range 2-18 weeks), and 75% of symptomatic patients developed symptoms by 8 weeks. Later-stage cancer and worse quality of life (QOL) pretreatment were significantly associated with symptom development. Sixty-eight percent of symptomatic subjects had involvement of the hands; however, there was no difference in the mean change in grip strength (-2.9 kg versus -1.3 kg; P = 0.6). Among symptomatic subjects, 46% had evidence of focal tenosynovitis of the hands and feet on examination. Although some symptomatic subjects had new MRI abnormalities, Rheumatoid Arthritis Magnetic Resonance Imaging Scoring did not significantly change. CONCLUSION: The incidence of AI-associated musculoskeletal syndrome is more than 50%, with most women developing symptoms by 8 weeks. The key finding in symptomatic women was focal tenosynovitis of the hands and feet, without evidence of autoimmune disease or systemic inflammation. Later-stage cancer and poorer QOL were predictive of symptom development.
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Leilani Morales; Steven Pans; Robert Paridaens; Rene Westhovens; Dirk Timmerman; Johan Verhaeghe; Hans Wildiers; Karin Leunen; Frederic Amant; Patrick Berteloot; Ann Smeets; Erik Van Limbergen; Caroline Weltens; Walter Van den Bogaert; Luc De Smet; Ignace Vergote; Marie-Rose Christiaens; Patrick Neven Journal: Breast Cancer Res Treat Date: 2006-10-24 Impact factor: 4.872
Authors: A Buzdar; A Howell; J Cuzick; C Wale; W Distler; G Hoctin-Boes; J Houghton; G Y Locker; J M Nabholtz Journal: Lancet Oncol Date: 2006-08 Impact factor: 41.316
Authors: A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias Journal: Lancet Date: 2005 Jan 1-7 Impact factor: 79.321
Authors: R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss Journal: Lancet Date: 2007-02-17 Impact factor: 79.321
Authors: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: Jessica A Martinez; Mihra S Taljanovic; Russell S Witte; Andres A Nuncio Zuniga; Betsy C Wertheim; C Kent Kwoh; Brian A Goldstein; Denise J Roe; Pavani Chalasani Journal: J Ultrason Date: 2021-03-08
Authors: Jessica A Martinez; Mihra S Taljanovic; Andres A Nuncio Zuniga; Betsy C Wertheim; Denise J Roe; Sima Ehsani; Sao Jiralerspong; Jennifer Segar; Pavani Chalasani Journal: J Clin Med Date: 2022-02-18 Impact factor: 4.241
Authors: Sameh Gomaa; Carly West; Ana Maria Lopez; Tingting Zhan; Max Schnoll; Maysa Abu-Khalaf; Andrew Newberg; Kuang-Yi Wen Journal: JMIR Form Res Date: 2022-06-21
Authors: Tara Hyder; Christopher C Marino; Sasha Ahmad; Azadeh Nasrazadani; Adam M Brufsky Journal: Front Endocrinol (Lausanne) Date: 2021-07-27 Impact factor: 5.555